Thyroid hormone resistance syndrome with P453T mutation in thyroid hormone receptor β gene
A pedigree report
Ayiguli Yusufu, BS^a, Wen-Jing Chen, BS^b, Ming-Chen Zhang, MD^a,^∗

Abstract
Rationale: Thyroid hormone resistance syndrome (THRS) is an inherited condition characterized by reduced responsiveness of target tissues to thyroid hormone. Due to their nonspecific symptomatic manifestations, these patients can be misdiagnosed. This study reports a pedigree with THRS caused by a mutation in the thyroid hormone receptor β (THRB) gene.

Patient concern: The proband, a 36-year-old woman at 19+4 weeks of gestation, was referred to our hospital because of abnormal thyroid function results. She was diagnosed with hyperthyroidism in October 2015, and had been treated with methimazole until her pregnancy.

Diagnosis: The proband and 2 of her children were diagnosed with THRS based on genetic analysis. Sequence analysis of the THRb gene showed a heterozygous mutation C>A located at exon 10. The mutation results in a change in proline for threonine at amino acid position 453, P453T.

Interventions: No treatment will fully and specifically correct the defect. All 3 patients were in normal metabolic status, and thus treatment was not required.

Outcomes: During a 2-year follow-up period, none of them had any complaints. The 20-year-old son (167 cm in height) and the 18-year-old daughter (150 cm in height) both had low academic performance.

Lessons: Elevated serum thyroid hormone (TH) levels associated with nonsuppressed thyroid-stimulating hormone (TSH) levels usually leads to the diagnosis of THRS. Genetic analysis provides a short cut to diagnosis and the treatment should be based on the patient’s clinical manifestations.

Abbreviations: FT3 = free triiodothyronine, FT4 = free thyroxine, NCBI = National Center for Biotechnology Information, PCR = Polymerase Chain Reaction, Tg = thyroglobulin, TgAb = thyroglobulin antibody, TH = thyroid hormone, TH(a/β) = thyroid hormone receptor(a/β), THRS = thyroid hormone resistance syndrome, TPOAb = thyroid antiperoxidase antibody, TRAb = thyrotropin receptor antibody, TSH = thyroid-stimulating hormone, TT3 = total triiodothyronine, TT4 = total thyroxine.

Keywords: gene mutation, thyroid hormone receptor, thyroid hormone resistance

1. Introduction
The thyroid hormone resistance syndrome (THRS), an inherited condition characterized by persistently elevated levels of free thyroxine (FT4) and free triiodothyronine (FT3) levels, while normal or mildly elevated thyroid-stimulating hormone (TSH) levels, was first reported in 1967. Mutations in the thyroid hormone receptor β (THRB) gene are responsible for 80% to 90% of THRS cases. Here, we describe a case of THRS that was suspected based on thyroid function findings. The diagnosis was confirmed by sequence analysis of the THRB gene, which showed a heterozygous missense mutation C>A located at exon 10.

2. Case presentation

2.1. Proband
A 36-year-old woman at 19+4 weeks of gestation was referred to Xinjiang Medical University affiliated First Hospital for abnormal thyroid function in August 2017. She was tested for thyroid function a week ago because of excessive sweating. There was no history of fatigueability, weakness, proptosis or diplopia,
palpitations, unusual bowel habits, or recent changes in weight. Upon physical examination: height 152 cm, body weight 60 kg, normal development, moderate skin temperature and elasticity, negative eye symptoms; a diffuse goiter with several small nodules, no tenderness, tremor or vascular murmur; heart rate 88 beats/min, no arrhythmia; no hands shaking or edema in lower extremities. Laboratory findings: thyroid function is listed in Table 1. Thyroid ultrasound showed a normal thyroid gland with some nonspecific nodules. The patient refused to undergo magnetic resonance imaging of the pituitary. The results of complete blood count, routine urinalysis, blood glucose, and renal function were all within normal ranges. She had no family history of thyroid disease. Past history showed that the patient had been diagnosed with hyperthyroidism for 2 years. Two years ago, she visited the hospital for lower abdominal pain and was diagnosed with hyperthyroidism after related inspections. Previous medical records showed abnormal thyroid function indicated by increased serum FT3 and FT4 levels, whereas TSH levels were decreased. The patient refused to undergo c nodules. She was treated with methimazole orally once per day for 10 mg. The proband visited the hospital several times and the methimazole dosage had been repeatedly adjusted (10–30 mg/d). However, thyroid function was not restored and medication was discontinued by herself because of pregnancy. During hospitalization, she was diagnosed with THRS based on genetic analysis and no medication was given.

2.2. Kindreds

Three generations of the pedigree are presented in Fig. 1. The family had no history of consanguineous marriage. Neither the proband’s parents nor her sibling had any history or symptoms of thyroid dysfunction, but their thyroid function and genotype were not available. Her eldest son (III:1) and daughter (III:2), aged 18 and 16 years, respectively, did not have any symptoms of hyperthyroidism or hypothyroidism, but they were shorter than their peers. The eldest son had a height of 167 cm (approximately –1SD on standard growth charts) and the daughter had a height of 150 cm (approximately –2SD on standard growth charts), while both had low academic performance. Their thyroid functions suggested that serum TT3, FT3, TT4, and FT4 levels were increased, while TSH levels were mildly elevated. The proband’s youngest son was 49 cm tall weighted 3.6 kg of an uneventful 40-week gestation and normal vaginal delivery. His thyroid function was normal. No abnormal signs on physical examination were found in these 3 children. The thyroid function results are shown in Table 2. During a 2-year follow-up period, 3 children had no complaints and their physical exams were normal.

3. Methods

3.1. Data collection

Clinical materials and peripheral blood samples of the proband and her children were collected. Thyroid function parameters were detected by chemiluminescence immunoassay (Roche cobas6000). This study was ethically prepared and approved by the ethics committee of Xinjiang Medical University affiliated First Hospital, and the informed consent was obtained from all subjects for the publication.

3.2. Genetic detection

The peripheral venous blood (10 mL) was obtained from the proband and her children, and was sent to Ruijin Hospital, Shanghai Jiaotong University School of Medicine for gene sequencing. PCR-DNA sequencing was used to examine all 10 exons of the THRβ gene. The primers of 10 exons and adjacent intronic were designed according to the THRβ gene sequence.

Table 1

| Date         | FT3 (3.1–6.8 pmol/L) | TT3 (1.2–3.1 nmol/L) | FT4 (12–22 pmol/L) | TT4 (66–181 nmol/L) | TSH (0.27–4.2 uIU/mL) | TRAb (0–1.75 IU/L) | Tg (3.5–77 ng/mL) | TgAb (0–115 IU/mL) | TPOAb (0–348 IU/mL) |
|--------------|----------------------|----------------------|--------------------|---------------------|-----------------------|---------------------|-------------------|-------------------|-------------------|
| 2015.10.21   | 9.25                 | 38.08                | –                  | –                   | 3.22                  | 1.41                | –                 | –                 | –                 |
| 2015.10.22   | 10.48                | 3.49                 | 42.57              | 238.80              | 4.74                  | –                   | –                 | –                 | –                 |
| 2015.11.10   | 9.90                 | 3.62                 | 41.61              | 216.20              | 3.93                  | –                   | 103.10            | –                 | 19.73             |
| 2015.12.07   | 8.61                 | 3.14                 | 33.65              | 188.10              | 2.80                  | –                   | 135.80            | –                 | 10.59             |
| 2016.01.25   | 8.99                 | 2.99                 | 33.46              | 198.70              | 6.41                  | –                   | –                 | –                 | –                 |
| 2017.08.04   | 6.65                 | 3.60                 | 25.06              | 203.40              | 4.57                  | 1.40                | –                 | 10.48             | 15.52             |

FT3 = free triiodothyronine; FT4 = free thyroxine; Tg = thyroglobulin; TgAb = thyroglobulin antibody; TPOAb = thyroid peroxidase antibody; TSH = thyroid-stimulating hormone; TT3 = total triiodothyronine; TT4 = total thyroxine.

The bold values in Table 1 and 2 indicates this value is outside the normal reference range.
THR R438H, R243Q, and P453T. In recent years, the point most frequently reported mutation sites are: R338W, A317T, and others located in exon 7, most located in exons 9, 10. The 5 most frequently reported mutation sites are: R338W, A317T, R438H, R243Q, and P453T. In recent years, the point mutations reported in China include A297T, R383H, and M442T. The THR gene mutation found in our case is located in exon 10 at P453T, which is one of the hot spots reported abroad. It has only been reported in another Chinese girl with the same mutation. At present, >160 mutations have been identified. Previous studies have confirmed that there is no clear correspondence between THR genotypes and phenotypes. Different families, patients in the same family, and different ages of onset can have different clinical manifestations. Formerly, THRS was categorized into generalized, isolated pituitary, and peripheral tissues. Based on symptoms and signs, this classification has not a logical basis now, because the former 2 are encountered in individuals with the same mutation and the latter represents the development of tolerance to the ingestion of excess thyroid hormone. The variable phenotype of THRS has multiple mechanisms. The clinical manifestations of THRS are highly heterogeneous, including hyperthyroidism, hypothyroidism, and nontoxic goiter. Goiter is the most common sign of THRS, and it is often the primary cause of medical attention. Other common symptoms include hyperactivity, learning disabilities, developmental delay, and sinus tachycardia. The severity of the disease is also uneven, ranging from asymptomatic to extremely severe symptoms, especially in childhood. Therefore, attention should be paid to THRS screening in children with the above clinical manifestations. At the same time, most THRS patients have familial heritability, so attention should also be paid to the screening of patients with a positive family history. Genetic diagnosis is currently the most reliable method for diagnosing patients with THRS. However, the gene defect in 15% of subjects with THRS remains unknown. The diagnosis cannot be ruled out for patients with suspected THRS who do not find mutations in genetic testing, and further tests, such as the TRH stimulation test, somatostatin suppression test, and T3 test, must be combined to confirm the diagnosis.

THRS is a hereditary disease and there is currently no cure for it. Fortunately, in most subjects with THRS, the partial tissue resistance to TH is adequately compensated for by an increase in the endogenous supply of TH and thus treatment is not required. Most importantly, it is not to intervene with the sole purpose of normalizing the TH levels. The patient’s symptoms and clinical picture should be concentrated instead of normalizing their thyroid function. The clinician should consider the patient's age, symptoms, and response to previous treatments. Sinus tachycardia is very common and can be controlled with β-blockers. Regarding goiter, super physiological doses of L-triiodothyronine given every other day aiming to suppress TSH can reduce the size of the gland and the effective level of TSH suppression is assessed by the suppression of serum Tg. THRS patients with hypothyroidism should be treated with TH starting with a small dose and gradually increasing the dose. The effective dose varies from person to person. Children with growth and developmental disorders, mental retardation, and delayed bone healing should be diagnosed early and treated with a high dose of TH to maintain normal intelligence and growth. Factors such as linear growth, bone maturation, and mental development must be considered when adjusting doses of drugs.

### Table 2

| Date       | FT3 (3.1–6.8 pmol/L) | TT3 (1.2–3.1 nmol/L) | FT4 (12–22 pmol/L) | TT4 (66–81 nmol/L) | TSH (0.27–4.2 uIU/mL) | TRAb | Tg (0.3–77 ng/mL) | TgAb | TPOAb |
|------------|----------------------|----------------------|--------------------|--------------------|-----------------------|------|-------------------|------|--------|
| 2017.08.09 | 10.78                | 3.87                 | 37.88              | 214.30             | 8.30                  | <0.5 | 29.80             | 12.30| 10.90  |
| 2017.08.09 | 11.26                | 4.18                 | 37.73              | 218.60             | 14.12                 | 0.36 | 47.08             | 13.44| 8.31   |
| 2018.03.07 | 6.27                 | 15.50                | –                  | 2.42               | 25.99                 | –    | –                 | –    | –      |

FT3 = free triiodothyronine; FT4 = free thyroxine; Tg = thyroglobulin; TgAb = thyroglobulin antibody; TRAb = thyroid-stimulating hormone; TgAb = total thyroglobulin antibody; TPOAb = thyroid peroxidase antibody; TSH = thyroid-stimulating hormone; TT3 = total triiodothyronine; TT4 = total thyroxine. The bold values in Table 1 and 2 indicates this value is outside the normal reference range.

Provided by NCBI (NM_000461.4). Primer synthesis, PCR reaction, and sequencing were completed by the Shanghai Institute of Endocrine and Metabolic Diseases. The sequencing results were compared with the NM_000461.4 sequence to identify the mutation sites.

### 4. Results

PCR amplification of the THRβ gene of the proband followed by gene sequencing showed a heterozygous missense mutation c1357C>A located at exon 10. The mutation caused a change in thyroid hormone receptor β protein amino acid 433 proline to threonine, p.Pro433Thr. Sequencing exon 10 of her eldest son and daughter found that they both had p. Pro433Thr heterozygous pathogenic variation in THRβ gene. The youngest son did not undergo gene sequencing because of the presence of a chemically euthyroid.

### 5. Discussion

THRS, characterized by decreased thyroid hormone sensitivity in different degrees to the target tissues, is a rare genetic disease with an incidence of approximately 1/40,000. Its characteristic manifestations include goiter, physical deformity, learning disability, inattention, mental abnormality, and mental retardation. THRS is a rare cause of thyroid dysfunction and is prone to misdiagnosis and missed clinical diagnosis. Therefore, it is necessary to summarize and analyze this rare case.

Thyroid hormone receptors are encoded by 2 genes (THRA and THRβ), and THRS is usually caused by mutations in THRβ. The majority of the mutations are located in 3 clusters enriched with CpG dinucleotide hot spots in the carboxy terminus of THRβ. The THRβ gene contains 10 exons and encodes a total of 461 amino acids. Among them, exons 7 to 10 encode amino acids 178 to 461, which constitute the carboxy-terminal ligand-binding domain and part of the hinge region. Almost all mutations discovered so far are concentrated in the 3 “hot spots” between exons 7 and 10 (234–282, 310–353, 429–461), and only A229T, R243W, and R243Q in the mutation site are located in exon 7, most located in exons 9, 10. The 5 most frequently reported mutation sites are: R338W, A317T, R438H, R243Q, and P453T. In recent years, the point mutations reported in China include A297T, R383H, and M442T. The THR gene mutation found in our case is located in exon 10 at P453T, which is one of the hot spots reported abroad. It has only been reported in another Chinese girl with the same mutation. At present, >160 mutations have been identified. Previous studies have confirmed that there is no clear correspondence between THR genotypes and phenotypes. Different families, patients in the same family, and different ages of onset can have different clinical manifestations. Formerly, THRS was categorized into generalized, isolated pituitary, and peripheral tissues. Based on symptoms and signs, this classification has not a logical basis now, because the former 2 are encountered in individuals with the same mutation and the latter represents the development of tolerance to the ingestion of excess thyroid hormone. The variable phenotype of THRS has multiple mechanisms. The clinical manifestations of THRS are highly heterogeneous, including hyperthyroidism, hypothyroidism, and nontoxic goiter. Goiter is the most common sign of THRS, and it is often the primary cause of medical attention. Other common symptoms include hyperactivity, learning disabilities, developmental delay, and sinus tachycardia. The severity of the disease is also uneven, ranging from asymptomatic to extremely severe symptoms, especially in childhood. Therefore, attention should be paid to THRS screening in children with the above clinical manifestations. At the same time, most THRS patients have familial heritability, so attention should also be paid to the screening of patients with a positive family history. Genetic diagnosis is currently the most reliable method for diagnosing patients with THRS. However, the gene defect in 15% of subjects with THRS remains unknown. The diagnosis cannot be ruled out for patients with suspected THRS who do not find mutations in genetic testing, and further tests, such as the TRH stimulation test, somatostatin suppression test, and T3 test, must be combined to confirm the diagnosis.

THRS is a hereditary disease and there is currently no cure for it. Fortunately, in most subjects with THRS, the partial tissue resistance to TH is adequately compensated for by an increase in the endogenous supply of TH and thus treatment is not required. Most importantly, it is not to intervene with the sole purpose of normalizing the TH levels. The patient’s symptoms and clinical picture should be concentrated instead of normalizing their thyroid function. The clinician should consider the patient’s age, symptoms, and response to previous treatments. Sinus tachycardia is very common and can be controlled with β-blockers. Regarding goiter, super physiological doses of L-triiodothyronine given every other day aiming to suppress TSH can reduce the size of the gland and the effective level of TSH suppression is assessed by the suppression of serum Tg. THRS patients with hypothyroidism should be treated with TH starting with a small dose and gradually increasing the dose. The effective dose varies from person to person. Children with growth and developmental disorders, mental retardation, and delayed bone healing should be diagnosed early and treated with a high dose of TH to maintain normal intelligence and growth. Factors such as linear growth, bone maturation, and mental development must be considered when adjusting doses of drugs.
In conclusion, we have reported a pedigree of THRS with heterozygous P453T mutation in the THRβ gene. The diagnosis of this syndrome is based on genetic analysis. The treatment of THRS should be based on its clinical manifestations, not the need to normalize thyroid hormone levels. Our findings provide insight into the diagnosis and treatment of THRS.

Author contributions
Conceptualization: Ming-Chen Zhang.
Data curation: Ming-Chen Zhang, Ayiguli Yusufu.
Funding acquisition: Ming-Chen Zhang.
Investigation: Ayiguli Yusufu.
Methodology: Ming-Chen Zhang.
Resources: Ming-Chen Zhang.
Software: Ayiguli Yusufu, Wen-Jing Chen.
Writing – original draft: Ayiguli Yusufu.
Writing – review & editing: Ming-Chen Zhang.

References
[1] Refetoff S, Dewind LT, Degroot LJ. Familial syndrome combining deaf-mutism, stippled ephyses, goiter and abnormally high pbi: possible target organ refractoriness to thyroid hormone. J Clin Endocrinol Metab 1967;27:279–94.
[2] Esquiavetoaun AM, Zantutwittmann DE, Petroli RJ, et al. Two novel mutations in the thyroid hormone receptor β in patients with resistance to thyroid hormone (RTHβ): clinical, biochemical, and molecular data. Horm Metab Res 2015;47:889–94.
[3] Yu C, Zhao J, Yao J, et al. Pituitary resistance to thyroid hormone caused by a novel mutation (H435A) in the thyroid hormone receptor beta: a case report. Medicine (Baltimore) 2018;97:e10544. doi: 10.1097/MD.0000000000010544.
[4] Wakasaki H, Matsumoto M, Tamaki S, et al. Resistance to thyroid hormone complicated with type 2 diabetes and cardiomyopathy in a patient with a TRβ mutation. Intern Med 2016;55:3295–9.
[5] Pappa T, Refetoff S. Human genetics of thyroid hormone receptor beta: resistance to thyroid hormone beta (RTHβ). Methods Mol Biol 2018;1801:225–40.
[6] Kim JH, Park TS, Back HS, et al. A newly identified insertion mutation in the thyroid hormone receptor-β gene in a Korean family with generalized thyroid hormone resistance. J Korean Med Sci 2007;22:560–3.
[7] Yen PM. Molecular basis of resistance to thyroid hormone. Trends Endocrinol Metab 2003;14:327–33.
[8] Wang BA, Wang M, Lu JM, et al. Pedigree analysis of a pituitary-resistance to thyroid hormone syndrome family caused by heterozygous A317T mutation in thyroid hormone receptorβ gene. Chin J Endocrinol Metab 2017;33:215–9. [Chinese].
[9] Chen J, Huang XD, Lin Y, Wang J, Shen CR. A novel mutation (A279T) of thyroid hormone receptor beta gene in resistance to thyroid hormone syndrome: a case report. J Clin Pediatr 2019;37:609–11. [Chinese].
[10] Shao F, Zhang XW, Shen SM, et al. Thyroid hormone resistance syndrome caused by R383H mutation of THRβ. Zhejiang Med J 2018;40:2597–8. [Chinese].
[11] Teng XC, Jin T, Wang RR, et al. Report of the first case of thyroid resistance syndrome in China caused by M442T mutation of TRβ. Chin J Pract Intern Med 2016;36:84–6. [Chinese].
[12] Teng XC, Jin T, Wang RR, et al. One case of a thyrotropin-secreting microadenoma and resistance to thyroid hormone with P453T mutation in TRβ gene. Chin J Endocrinol Metab 2016;1:19–23. [Chinese].
[13] Singh BK, Yen PM. A clinician’s guide to understanding resistance to thyroid hormone due to receptor mutations in the TRα and TRβ isoforms. Clin Diabetes Endocrinol 2017;3:8. doi: 10.1186/s40842-017-0046-z.
[14] Ferrara AM, Onigata K, Ercan O, et al. Homozygous thyroid hormone receptor β-gene mutations in resistance to thyroid hormone: three new cases and review of the literature. J Clin Endocrinol Metab 2012;97:1328–36.
[15] Refetoff S, Dumitrescu AM. Syndromes of reduced sensitivity to thyroid hormone: genetic defects in hormone receptors, cell transporters and deiodination. Best Pract Res Clin Endocrinol Metab 2007;21:273–305.
[16] Kong YH. Advances in diagnosis and treatment of thyroid hormone resistance syndrome. J Clin Pathol Res 2016;3:39. doi: 10.1039/c9md00004j.
[17] Jang XH, Fang WY, Ye L, et al. Approach to the patients with resistance to thyroid hormone. Chin J Endocrinol Metab 2013;29:165–9. [Chinese].
[18] Rivas AM, Lado-Abeal J. Thyroid hormone resistance and its management. Proc (Bayl Univ Med Cent) 2016;29:209–11.
[19] Anselmo J, Refetoff S. Regression of a large goiter in a patient with resistance to thyroid hormone by every other day treatment with triiodothyronine. Thyroid 2004;14:71–4.